ProfileGDS5678 / 1431313_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 35% 36% 36% 37% 36% 34% 34% 35% 36% 36% 35% 36% 35% 36% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.8217335
GSM967853U87-EV human glioblastoma xenograft - Control 22.8115136
GSM967854U87-EV human glioblastoma xenograft - Control 32.815336
GSM967855U87-EV human glioblastoma xenograft - Control 42.783137
GSM967856U87-EV human glioblastoma xenograft - Control 52.7760836
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.8472634
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.837234
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.7957635
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.7922236
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.8099436
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.7947235
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.794936
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.8062435
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.8053736